According to research data:
In healthy volunteers taking standard doses, the half-life of the drug (time required for the concentration in the body to decrease by half) is approximately 3 hours. In patients with hematologic disorders (such as multiple myeloma or myelodysplastic syndromes), the half-life ranges from 3 to 5 hours.
However, there is currently no authoritative data specifying the total duration of therapeutic effect exerted by the drug in the body.
